Leon-nanodrugs GmbH (Munich) is a nanotechnology-based drug development company focused on development of novel oral and parenteral pharmaceutical formulations and innovative drug combinations. Leon’s proprietary MJR® Technology platform provides a solution to overcome one of the key issues of most marketed therapeutics, poor water solubility, a pre-requisite for drug uptake into the body. Leon-nanodrugs has established CDMO partnerships in Europe and the US to enable access to key international markets. Leon’s first own product developed based on the MJR® Technology is planned to be submitted for Marketing Authorization in 2017.
Leon-nanodrugs offers access to the next generation nano formulated drugs with added patient benefits and economical values for its partners and shareholders